The Food and Drug Administration said that it remains concerned that certain types of birth control pills increase the risk of blood clots. The FDA has previously cited two recent studies that have reported a greater risk of blood clots for women on birth control pills containing drospirenone, such as Yasmin, compared with women taking birth control pills containing a different hormone. The study involved 800,000 women and found about a 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing birth control pills, such as Yaz, compared to users of other hormonal contraceptives.
Two older studies conducted as part of the post marketing requirements for the FDA found no difference in blood clotting risks between the two comparable groups of birth control pills.
The FDA said it will continue to look into the matter and will not reach a conclusion until a meeting of scientific panels takes place in December.
Birth-control pills that contain blood clotting drospirenone include Bayer’s Yaz, Yasmin, Beyaz, Safyral, Sandoz’s Syeda and Loryna. Barr Laboratories’ Ocella, Watson Pharmaceuticals’ Zarah and Teva Pharmaceuticals’ Loryna also contain drospirenone.
As a precaution, the FDA warns women to consult a medical professional before deciding whether or not to stop taking birth control pills that contain drospirenone. Most birth control pills contain two types of hormones, estrogen and progestin. All types of pills increase the risk of blood clots. Product labels warn women of increased risk of blood cloths while taking birth control pills.